baminercept

Recombinant proteinexperimental

Clinical trial activity

8 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
7
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2005 (NCT00292422)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • baminercept
  • baminercept
  • bg9924
  • bg-9924
  • tt-47

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01552681Phase 2Jul 1, 2012Biogen, Duke University, National Institute of Allergy and Infectious Diseases (NIAID), Oklahoma Medical Research Foundation
NCT01164384Phase 1Oct 1, 2010University of Zurich
NCT01181089Phase 1/Phase 2 (Phase 2)Sep 1, 2010Biogen
NCT00664573Phase 2Nov 1, 2007Biogen
NCT00523328Phase 2Aug 1, 2007Biogen
NCT00664716Phase 2Jul 1, 2007Biogen
NCT00458861Phase 2Mar 1, 2007Biogen
NCT00292422Phase 2Nov 1, 2005Biogen
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BiogenFor profit7612005
Duke UniversityAcademic/Hospital1012012
National Institute of Allergy and Infectious Diseases (NIAID)Government1112012
Oklahoma Medical Research FoundationAcademic/Hospital1012012
University of ZurichAcademic/Hospital1112010
5 organizations
Page 1 / 1